Benzimidamides compounds comprising an oxaborinin ring

US11352372B2 · kind B2 · utility

Assignee

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR

Inventors

• John Liddle · Stevenage, GB
• Ann Louise Walker · Stevenage, GB
• Gemma Victoria White · Stevenage, GB
• Alexis Denis · Paris, FR
• Nerina Dodic · Les Ulis, FR
• Marie-Hélène FOUCHET · Paris, FR
• Anne Marie Jeanne Bouillot · Les Ulis, FR

Key dates

• Filing date: Jun 5, 2019
• Grant date: Jun 7, 2022
• Expiry date: Jun 7, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P17/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.